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Summary  Several  guidelines  base  the  empirical  therapy  of  ventilator-associated
pneumonia  (VAP)  on  the  time  of  onset.  However,  there  is  emerging  evidence  that
the  isolated  microorganisms  may  be  similar  regardless  of  onset  time.  This  study
evaluated  the  characteristics  and  outcomes  of  VAP  with  different  onset  times.  All
of  the  mechanically  ventilated  patients  admitted  to  the  ICU  of  a  900-bed  tertiary-
care  hospital  between  01/08/2003  and  31/12/2010  were  prospectively  followed  for
Abbreviations: VAP, ventilator associated pneumonia; ICU, intensive care unit; MV, mechanical ventilation; NHSN, National Health-
are Safety Network; HAI, healthcare-associated infection; MDRO, multi-drug resistant organism; EE-VAP, early onset VAP/early
ospital admission; EL-VAP, early onset VAP/late hospital admission; LL-VAP, late-onset/late hospital admission; HR, hazard ratios;
Is, conﬁdence intervals.
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VAP  development  according  to  the  National  Healthcare  Safety  Network  criteria.  The
patients  were  categorized  into  four  groups:  EO  if  VAP  occurred  within  4  days  of  intu-
bation  and  hospital  admission;  LO  if  VAP  occurred  after  4 days  of  admission;  EL  if  VAP
occurred  within  4  days  of  intubation,  but  after  the  fourth  hospitalization  day;  and  LL
if  VAP  occurred  after  the  fourth  day  of  intubation  and  hospitalization.  Out  of  the  394
VAP  episodes,  63  (16%)  were  EO  episodes,  331  (84.0%)  were  LO  episodes,  40  (10.1%)
were  EL  episodes  and  291  (73.1%)  were  LL  episodes.  The  isolated  microorganisms
were  comparable  among  the  four  groups,  with  a  similar  rate  of  potentially  multidrug
resistant  organisms  in  the  EO-VAP  (31.7%),  LO-VAP  (40.8%),  EL-VAP  (37.5%)  and  LL-VAP
(43.3%)  samples.  The  hospital  mortality  was  24%  for  EO-VAP  cases,  28%  for  LO-VAP
cases,  40%  for  EL-VAP  cases  and  49%  for  LL-VAP  cases.  However,  in  the  adjusted  multi-
variate  analysis,  neither  LO-VAP,  EL-VAP  nor  LL-VAP  was  associated  with  an  increased
risk  of  hospital  mortality  compared  with  EO-VAP  (OR,  0.86  95%  CI,  0.34—2.19;  1.22;
95%  CI,  0.41—3.68,  and  0.95;  95%  CI,  0.43—2.10,  respectively).  In  this  study,  the  occur-
rence  of  potential  multidrug  resistant  pathogens  and  the  mortality  risk  were  similar
regardless  of  VAP  timing  from  hospital  admission  and  intubation.  The  bacterial  iso-
lates  obtained  from  the  VAP  cases  did  not  follow  an  early  vs.  late-onset  pattern,  and
thus,  these  terms  may  not  be  clinically  helpful.
Microbiology;
Outcomes;
Critically  ill
©  2015  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
Limited.  All  rights  reserved.
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trauma adult  ICU  at  King  Abdulaziz  Medical  City
in Riyadh,  Saudi  Arabia,  from  August  1,  2003,  to
December  31,  2010.  The  ICU  admitted  approxi-Introduction
Ventilator-associated  pneumonia  (VAP)  is  a  com-
mon device-related  healthcare-associated  infec-
tion (HAI),  with  an  incidence  in  critically  ill  patients
ranging between  6  and  52%  [1—3].  VAP  remains  a
principal  cause  of  morbidity,  mortality  and  eco-
nomic burden  in  intensive  care  units  (ICUs)  [4]. In  a
recent study,  VAP  was  the  third  most  common  HAI
infection,  accounting  for  31.7%  of  the  annual  cost  of
HAIs to  the  American  health  care  system  [5]. Addi-
tionally,  it  accounts  for  approximately  half  of  all
antibiotics  prescribed  to  critically  ill  patients  [6].
The concept  of  early  and  late-onset  VAP  was
introduced in  1986  by  Mandelli  and  colleagues
[7].  Traditionally,  early  onset  VAP  is caused  by
antibiotic-sensitive  bacteria  and  has  a  better  prog-
nosis. In  contrast,  late-onset  VAP  is  more  likely  to  be
caused by  multi-drug  resistant  organisms  (MDROs)
and is  associated  with  increased  mortality  and  mor-
bidity [8].  However,  there  is widespread  variation
among researchers  in  deﬁning  the  exact  time  that
differentiates  early  from  late  VAP,  with  the  time
for ‘‘early’’  ranging  from  2  to  6 days  in  the  pub-
lished  data  [8—17]. Conﬂict  also  exists  in  selecting
the inception  point;  is it  the  date  of  admission  or
the date  of  intubation/device?  [8—17]
Uncertainty  exists  in  the  current  literature  as  to
whether  the  classiﬁcation  of  early  vs.  late  VAP  is
m
o
dlinically  important  [11,17—20]. Furthermore,  this
abeling does  not  clearly  account  for  ‘‘early  onset
AP’’ in  patients  with  prolonged  hospital  stays.
ompared  with  patients  who  are  recently  admit-
ed and  develop  ‘‘early  onset  VAP,’’  patients  with
xtended  hospitalization  who  subsequently  develop
‘early onset  VAP’’  may  constitute  a  special  popu-
ation, with  distinctive  risk  factors  and  microbial
ora, thus  requiring  careful  thought  when  select-
ng their  empiric  antibiotic  regimen  and  prevention
easures. Therefore,  we  performed  this  study  to
scertain  if in  fact  this  categorization  still  bears
ny medical  signiﬁcance  and  also  to  assess  the  most
revalent  microorganisms  responsible  for  VAP  in
hese groups.
aterials and methods
atients and setting
his  prospective  observational  cohort  study  was
erformed  in  a  21-bed  closed  medical-surgical-ately 900  patients  annually  and  was  covered  by
nsite board-certiﬁed  intensivists  24  h  per  day,  7
ays per  week  [21]  with  a nurse-to-patient  ratio
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fhe  impact  of  onset  time  on  the  isolated  pathogen
f  approximately  1:1.  The  hospital  was  a  900-bed
ertiary-care  center,  accredited  by  the  Joint  Com-
ission  International,  and  had  an  active  Infection
revention  and  Control  Program  that  collaborated
ith the  ICU  medical  and  nursing  staff  to  ensure  the
mplementation  and  monitoring  of  infection  control
ractices.  In  this  study,  all  patients  on  mechanical
entilation (MV)  for  more  than  48  h  were  prospec-
ively followed  during  their  ICU  stay.  We  excluded
atients who  were  transferred  from  other  hospital
s well  as  patients  with  burns,  do-not-resuscitate
rders and  brain  death.  The  Institutional  Review
oard and  King  Abdullah  International  Medical
esearch Center  ethics  committees  of  National
uard Health  Affairs,  Riyadh,  approved  this  study
nd waived  the  requirement  for  informed  consent
ecause this  was  a  prospective  observational  study
sing data  commonly  documented  for  all  patients
n our  ICU  department.
iagnosis, deﬁnition and classiﬁcation of
entilator associated pneumonia
ne  investigator  made  daily  rounds  in  the  ICU
o identify  patients  with  clinical  signs  of  VAP.
ll patients  with  suspected  VAP  were  prospec-
ively and  independently  reviewed  by  another
nvestigator, who  conﬁrmed  the  diagnosis.  VAP
as deﬁned  as  pneumonia  that  developed  more
han 48  h  after  endotracheal  intubation  [8,9,22].
AP was  diagnosed  clinically  based  on  the  Cen-
ers for  Disease  Control  and  Prevention  criteria
s two  or  more  serial  chest  radiographs  with
t least  1  of  the  following:  new,  progressive,
r persistent  inﬁltrates;  consolidation;  or  cavita-
ion;  with  two  of  the  following:  core  temperature
38.5 or  ≤36 ◦C;  leukocytosis  (≥12,000  mm−3);
eukopenia  (white  blood  cell  <1500  mm−3);  or  new
nset  purulent  bronchial  secretions,  without  other
auses  and  a  signiﬁcant  positive  culture  from
lood, bronchoalveolar  lavage  or  endotracheal
spirate, or  a  culture  from  another  relevant  site  of
nfection [23].
In  this  study,  the  patients  were  categorized  into
our groups  depending  on  the  timing  of  VAP  onset
rom  intubation  and  hospital  admission:  (1)  the
arly onset  (EO)-VAP  group  included  patients  who
eveloped  VAP  within  the  ﬁrst  4  days  of  invasive
echanical ventilation  and  of  hospitalization;  (2)
he late-onset  (LO)-VAP  group  included  those  who
eveloped  VAP  after  the  fourth  day  of  hospital-
zation; (3)  the  early  late  (EL)-VAP  group  included
hose  who  developed  VAP  within  the  ﬁrst  4  days  of
ntubation,  but  after  the  fourth  day  of  hospitaliza-
ion; and  (4)  the  late-late  (LL)-VAP  group  included
d
s
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hose  who  developed  VAP  after  the  fourth  day  of
ntubation  and  hospitalization  [8—10,24].
We deﬁned  Pseudomonas  aeruginosa, Acineto-
acter baumannii  and  Klebiella  pneumoniae  as
otential  multi-drug  resistant  organisms  (MDROs)
25]. All  patients  were  followed  to  hospital  dis-
harge,  and  only  the  ﬁrst  episode  of VAP  was
ncluded in  this  study.
ampling
ll  patients  with  clinical  criteria  indicative  of
AP underwent  endotracheal  aspiration  sampling.
ndotracheal  aspiration  was  performed  with  a
terile technique  using  a  50-cm,  10—12  F  suction
atheter (Tyco;  Tyco  Healthcare  Ireland  Limited,
reland) with  a mucus  collection  tube  (Mucus  Trap;
msino  International  Inc.;  Pomona,  California).  The
atheter was  introduced  through  the  endotracheal
ube for  at  least  30  cm.  Gentle  suctioning  was
erformed, and  the  aspirate  (volume  ≥1  mL)  was
ollected  for  evaluation  [26].
icrobiology
ndotracheal  aspirate  cultures  were  collected  in  a
terile sputum  trap  and  then  sent  to  the  microbi-
logy laboratory.  The  specimens  were  then  plated
n sheep  blood  agar,  chocolate,  and  MacConkey
gar. All  plates  were  incubated  for  at  least  48  h
n a 5%  carbon  dioxide  incubator  at  37 ◦C.  The
solates were  characterized  by  colony  morphology
nd Gram  staining.  The  microbiological  growth  of
he endotracheal  aspirate  was  classiﬁed  as  rare,
ight, moderate,  or  heavy  based  on  the  number
f colonies  on  the  plate.  The  identiﬁcation  of
he organism  was  performed  using  a  Vitek® II  sys-
em (North  Carolina,  USA)  and  API  20E® test  kits
bioMerieux,  Inc.,  Missouri,  USA).  The  susceptibility
f the  clinical  isolates  to  antibiotics  was  deter-
ined by  the  Vitek® II  system  (North  Carolina,  USA),
hile the  E-test  was  used  for  conﬁrmation  when
ecessary.
If multiple  organisms  were  isolated  from  a  sin-
le sample,  all  of  their  data  were  entered  in the
tatistical  analysis  (Table  2).
dditional collected data
he  same  investigator  recorded  other  relevant  data
y reviewing  the  patients’  medical  records.  The
ollowing  clinical  information  were  captured:  the
emographic  data,  admission  category  (medical,
urgical  or  trauma),  primary  admission  diagnosis
epending on  the  system  involved,  source  of  admis-
ion, patient’s  cute  physiology  and  chronic  health
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evaluation  (APACHE)  II score  [27],  injury  sever-
ity score  (ISS)  for  trauma  patients  [28],  presence
of chronic  illnesses  (diabetes  mellitus,  hyperten-
sion, chronic  obstructive  pulmonary  disease  or
an immunocompromised  state),  admission  Glas-
gow Coma  Scale  score  (GCS)  with  coma  deﬁned  as
GCS <9,  presence  of  shock  on  admission  deﬁned
as requiring  vasopressors  or  inotropes,  except
for dopamine  of  <5  g/kg/min,  ratio  of  the  par-
tial pressure  of  arterial  oxygen  to  the  fraction
of inspired  oxygen  (PaO2/FiO2) and  diagnosis  of
acute respiratory  distress  syndrome  [29]  on  ICU
admission.  Data  obtained  from  the  VAP  database
included the  location  where  the  intubation  was  per-
formed,  type  of  intubation  (elective  vs.  emergent),
presence of  pre-determined  VAP  risk  factors  (the
use of  nasogastric  vs.  orogastric  tubes,  witnessed
aspiration, use  of  H2 blockers,  neuromuscular
blockers  and  prior  antibiotic  therapy  for  >7  days,
traumatic  intubation,  unplanned  extubation,  and
failed extubation)  and  respiratory  culture  results.
Pseudomonas  aeruginosa, Acinetobacter  bauman-
nii and  Klebiella  pneumoniae  were  considered  to
be potential  MDROs.  We  also  recorded  the  following
outcomes from  the  ICU  database:  ICU  and  hospital
mortality,  tracheostomy  requirements,  duration  of
MV and  length  of  stay  in  the  ICU  and  hospital.
Statistical analysis
The  patient  demographics,  clinical  characteris-
tics, and  risk  factors  were  described  as  the
means with  standard  deviations  for  continuous
data or  frequencies  with  percentages  for  categor-
ical data.  Chi-square,  Fisher’s  exact  or  Student
t tests,  as  appropriate,  were  used  to  evaluate
differences  among  the  study  groups.  To  study
the impact  of  VAP  onset  timing  on  patient  out-
comes, we  ran  multivariate  logistic  regression
analyses. The  independent  variables  entered  in
the models  were  clinically  relevant  factors  and
the baseline  characteristics  that  were  signiﬁcantly
different among  the  groups  of  patients.  These
variables included:  age,  gender,  APACHE  II  score,
body mass  index,  GCS,  creatinine,  INR,  bilirubin,
admission diagnosis,  admission  category,  chronic
co-morbidities  (respiratory,  cardiovascular,  renal,
neurological),  diabetes,  hypertension,  vasopressor
use,  location  before  referral  to  the  ICU,  acute
respiratory distress  syndrome,  failed  extubation,
accidental extubation,  orogastric  vs.  nasogastric
tube and  prolonged  use  of  antibiotics.  The  results
for dichotomous  outcomes  (ICU  and  hospitality  and
tracheostomy)  are  presented  as  odds  ratios  (ORs)
with 95%  conﬁdence  intervals  (CIs).  The  results  of
continuous  outcomes  (ICU  and  hospital  length  of
a
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tay)  were  presented  as  beta  coefﬁcients  with  95%
Is. If the  regression  beta  coefﬁcient  is  positive,
he interpretation  is  that  for  every  1-unit  increase
n the  predictor  variable,  the  dependent  variable
ill increase  by  the  unstandardized  beta  coefﬁcient
alue. All  statistical  analyses  were  conducted  using
he Statistical  Analysis  System  (SAS,  version  9.0;
AS Institute,  Cary,  NC).
esults
atient characteristics
here  were  394  episodes  of  VAP  during  the  study
eriod. Of  these,  63  (16%)  were  EO-VAP,  331  (84%)
ere LO-VAP,  40  (10.1%)  were  EL-VAP  and  291
73.1%)  were  LL-VAP.  Table  1  describes  the  charac-
eristics  of  the  four  groups.  Patients  in  the  EO-VAP
roup were  younger  (35.2  ±  17.8  years);  had  lower
ody mass  indices  (25.6  ±  6.0  kg/m2),  APACHE  II
cores (19.6  ±  5.1),  and  higher  PaO2/FiO2 ratios
270 ±  99);  and  were  more  likely  to  be  intubated  in
83.9%) and  admitted  from  (69.8%)  the  emergency
epartment compared  with  those  with  LO-VAP.  Indi-
iduals in  the  EL-VAP  group  had  a similar  age,
ody mass  index,  PaO2/FiO2 ratio,  platelet  counts,
ource  of  referral  and  location  of  intubation,  but
 lower  APACHE  II  score  (21.8  ±  7.2  vs.  25.6  ±  9.2,
 =  0.01),  compared  to  those  in  the  LL-VAP
roup.
icrobiological patterns
he  VAP  microbiology  is  described  in  Table  2.  A  total
f 293  VAP-related  organisms  were  isolated  during
he study  period  from  August  1,  2003,  to  December
1, 2010.  There  were  56  organisms  (Gram  neg-
tive =  29  and  Gram  positive  =  17)  isolated  in  the
O-VAP  group  and  237  (Gram  negative  =  178  and
ram  positive  = 59)  in  the  LO-VAP  group.  There  were
8 episodes  of  VAP  with  more  than  one  organism  iso-
ated from  a  single  sample:  15  in  the  EO-VAP  group,
3 in  the  LO-VAP  group  (EL-VAP  =  4  and  LL-VAP  =  29).
Gram-negative  bacilli  were  the  most  frequently
solated agents  in  the  four  groups.  The  three
ost frequent  microorganisms  isolated  in  the  EO-
AP group  were  Hemophilus  inﬂuenzae  (25.4%),
cinetobacter  baumannii  (12.7%),  and  methicillin-
ensitive Staphylococcus  aureus  (MSSA)  (11.1%).
n the  EL-VAP  group,  the  most  common  microor-
anisms were  MSSA  (20%),  A.  baumannii  (15%)
nd Pseudomonas  aeruginosa  (15%).  In  the  LL-VAP
roup,  the  most  common  microorganisms  were  A.
aumannii (18.6%),  P.  aeruginosa  (16.2%),  Entero-
acter species  (5.5%)  and  MSSA  (5.5%).
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Table  1  Baseline  characteristics  of  patients  with  ventilator  associated  pneumonia  (VAP).  Early  onset  VAP  occurred
within  4  days  of  intubation  and  hospital  admission.  Late  onset  VAP  occurred  after  4  days  of  hospital  admission.
EL-VAP  occurred  within  4  days  of  intubation  but  after  the  fourth  day  of  hospitalization.  LL-VAP  occurred  after  the
fourth  day  of  intubation  and  hospitalization.
Variables  Early  onset
VAP
N  =  63
Late  onset
VAP
N  =  331
P-Value
EO-VAP  vs.
LO-VAP
EL-VAP
n  =  40
LL-VAP
n  =  291
P-Value
EL-VAP  vs.
LL-VAP
Age  (y),  mean  ±  SD  35.2  ±  17.8  46.5  ±  22.4  <0.0001  43.8  ±  25.1  46.8  ±  22.0  0.43
Male gender,  N  (%) 58  (92.1)  252  (76.1)  0.005  33  (82.5)  219  (75.3)  0.31
Body mass  index
(kg/m2),  mean  ±  SD
25.6  ±  6.0  27.7  ±  7.6  0.01  27.0  ±  7.7  27.8  ±  7.7  0.56
APACHE II  score,
mean  ±  SD
19.6  ±  5.1 25.1  ±  9.1 <0.0001  21.8  ±  7.2  25.6  ±  9.2  0.01
Glasgow Coma  Scale,
mean  ±  SD
7.2  ±  3.9 7.4  ±  4.0 0.66  7.6  ±  3.9  7.4  ±  4.0  0.77
Admission diagnostic  category,  N  (%)
Respiratory  1  (1.6)  78  (23.6)  11  (27.5)  67  (23.0)  0.55
Cardiovascular  7  (11.1)  79  (23.9)  <0.0001  4  (10.0)  75  (25.8)  0.03
Neurological  6  (9.5)  14  (4.2)  2  (5.0)  12  (4.1)  0.68
Comorbid conditions,  N  (%)
Chronic  respiratory
disease
2  (3.2)  62  (18.7)  0.002  5  (12.5)  57  (19.6)  0.28
Chronic cardiovascular
disease
5  (7.9)  52  (15.7)  0.11  4  (10.0)  48  (16.5)  0.29
Chronic kidney  disease  2  (3.2)  47  (14.2)  0.02  4  (10.0)  43  (14.8)  0.42
Chronic liver  disease  1  (1.6)  36  (10.9)  0.02  5  (12.5)  31  (10.7)  0.73
Immunocompromised
state
2 (3.2)  29  (8.8)  0.13  1  (2.5)  28  (9.6)  0.22
Vasopressors
requirement
42 (66.7)  232  (70.1)  0.59  25  (62.5)  207  (71.1)  0.26
Septic shock  9  (14.3)  86  (25.9)  0.05  6  (15.0)  80  (27.5)  0.09
Source of  referral,  N  (%)
Emergency
Department
44  (69.8)  118  (35.7)  16  (40.0)  102  (35.1)  0.60
Floor/ward  2  (3.2)  119  (35.9)  <0.0001  15  (37.5)  104  (35.7)  0.86
Operation room  17  (27.0)  94  (28.4)  9  (22.5)  85  (29.2)  0.46
Location of  intubation,  N  (%)
Emergency
Department
52  (83.9)  176  (61.8)  24  (66.7)  152  (61.0)  0.40
Operating room  5  (8.1)  37  (12.9)  0.003  2  (5.6)  35  (14.1)  0.28
Recovery room  5  (8.1)  72  (25.3)  10  (27.8)  62  (24.9)  0.68
Host risk  factors,  N  (%)
COPD  1  (1.6)  31  (9.4)  0.04  3  (7.5)  28  (9.6)  1.00
Diabetes 9  (14.3)  81  (24.5)  0.08  8  (20.0)  73  (25.1)  0.48
Aspiration risk  6  (9.5)  15  (15.4)  0.22  4  (10.0)  47  (16.2)  0.31
Other risk  factors,  N  (%)
H2-Blockers  58  (92.1)  304  (91.8)  0.95  35  (87.5)  269  (92.4)  0.35
Paralytic agent  9  (14.3)  66  (19.9)  0.29  7  (17.5)  59  (20.3)  0.68
Sedation 7  (11.1)  146  (44.1)  <0.0001  23  (57.5)  123  (42.3)  0.07
Orogastric tube  36  (57.1)  87  (26.3)  <0.0001  8  (20.0)  79  (27.2)  0.34
Nasogastric  tube  27  (42.9)  244  (73.7)  <0.0001  32  (80.0)  212  (72.9)  0.34
PaO2/FiO2 ratio,
mean  ±  SD
270  ±  99  203  ±  115  <0.0001  209  ±  103  202  ±  116  0.72
Platelet count,
mean  ±  SD
173  ±  60  202  ±  133  0.007  236  ±  147  197  ±  131  0.10
Bilirubin (mol/l),
mean  ±  SD
19.5  ±  15.3  43.1  ±  92.4  0.0001  52.3  ±  108.3  42.0  ±  90.5  0.57
Creatinine (mol/L),
mean  ±  SD
112.7  ±  107.4  135.1  ±  115.8  0.16  108.1  ±  83.6  138.8  ±  119.1  0.05
INR, mean  ±  SD  1.3  ±  0.5  1.5  ±  0.8  0.02  1.5  ±  1.1  1.5  ±  0.7  0.85
APACHE, acute physiology and chronic health evaluation; SD, standard deviation; INR, international normalized ratio; PaO2/FiO2,
partial pressure of arterial oxygen to the fraction of inspired oxygen; COPD, chronic obstructive pulmonary disease.
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Table  2  Microbiology  of  ventilator  associated  pneumonia. a Early  onset  VAP  occurred  within  4  days  of  intubation
and  hospital  admission.  Late  onset  VAP  occurred  after  4  days  of  hospital  admission.  EL-VAP  occurred  within  4  days
of  intubation  but  after  the  fourth  day  of  hospitalization.  LL-VAP  occurred  after  the  fourth  day  of  intubation  and
hospitalization.
Pathogen  Early  onset
VAP
N  =  63
Late  onset
VAP
N  =  331
P-Value
EO-VAP  vs.
LO-VAP
EL-VAP
n =  40
LL-VAP
n =  291
P-Value
EL-VAP  vs.
LL-VAP
Gram  negative
organisms,  N  (%)
34  (54.0) 161  (48.6) 0.44 20  (50.0) 141  (48.5) 0.85
Hemophilus
inﬂuenzae
16  (25.4)  7  (2.1)  <0.0001  1  (2.5)  6  (2.1)  0.60
Pseudomonas
aeruginosa
3  (4.8)  53  (16)  0.02  6  (15.0)  47  (16.2)  0.85
Acinetobacter
baumannii
8  (12.7)  60  (18.1)  0.29  6  (15.0)  54  (18.6)  0.58
Klebsiella
pneumoniae
6  (9.5)  17  (5.1)  0.17  3  (7.5)  14  (4.8)  0.44
Enterobacter  species  4  (6.4)  19  (5.7)  0.85  3  (7.5)  16  (5.5)  0.71
Escherichia  coli  1  (1.6)  6  (1.8)  0.90  2  (5.0)  4  (1.4)  0.16
Serratia  marcescens 1 (1.6)  10  (3)  0.52  0  10  (3.4)  0.61
Proteus  mirabilis 0 2  (0.6)  1.0  0  4  (1.4)  1.00
Stenotrophomonas
maltophilia
0  4  (1.2)  1.0  1  (2.5)  1  (0.34)  0.23
Gram  positive
organisms,  N  (%)
17  (27.0) 49  (14.8)  0.02  9  (22.5)  40  (13.8)  0.14
MSSA  7  (11.1) 24  (7.3) 0.31 8  (20.0) 16  (5.5)  0.003
MRSA  3  (4.8)  14  (4.2)  0.74  0  14  (4.8)  0.39
Streptococcus
pneumonia
5  (7.9)  8  (2.4)  0.04  1  (2.5)  7  (2.4)  1.00
Micrococcus  species  2  (3.2)  3  (0.9)  0.18  0  3  (1.0)  1.00
Other  organisms,  N  (%)  0  10  (3.0)  0.38  1  (2.5)  9  (3.1)  1.00
Culture  negative,  N
(%)
12  (19.0)  121  (36.6)  0.17  12  (30.0)  107  (36.0)  0.40
Potential  MDROs  and
MRSA,  N  (%)
20 (31.8)  135  (40.8)  0.18  13  (32.5)  122  (41.9)  0.26
MSSA, methicillin-sensitive Staphylococcus aureus;  MRSA, methicillin-resistant Staphylococcus aureus;  MDROs, multidrug-resistant
organisms.
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Compared  with  the  LO-VAP  group,  the  EO-VAP
group had  signiﬁcantly  higher  frequencies  of  H.
inﬂuenza  (25.4%  vs.  2.1%)  and  S.  pneumonia  (7.9%
vs. 2.4%),  but  lower  frequencies  of  P.  aeruginosa
(4.8% vs.  16.0%,  p  =  0.02).  The  isolated  pathogens
in the  EO-VAP  group  were  similar  to  those  in  the  EL-
VAP group,  except  for  H.  inﬂuenza  (2.5%  vs.  25.4%,
p =  0.002).  Additionally,  the  organisms  responsible
for EO-VAP  were  comparable  to  those  responsible
for LL-VAP,  except  for  H.  inﬂuenza  (25.4%  vs.  2.1%,
p =  0.0001)  and  S.  pneumonia  (7.9  vs.  2.4,  p = 0.04),
which were  more  common  in  EO-VAP  cases.  The
isolated  pathogens  for  EL-VAP  were  comparable  to
those isolate  from  LL-VAP,  except  for  MSSA  (20%  vs.
5.5%, p  =  0.003).
Methicillin-resistant  Staphylococcus  aureus
(MRSA) and  the  potential  MDROs  (P.  aeruginosa,
h
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w isolated: 15 in early onset VAP, 33 in late onset VAP (EL-VAP = 4
.  baumannii  and  K.  pneumonia) were  commonly
solated in  the  four  groups  (EO-VAP:  31.7%,  LO-VAP:
0.8%,  EL-VAP:  37.5%  and  LL-VAP:  43.3%).  While
. aeruginosa  was  signiﬁcantly  more  common  in
O-VAP and  LL-VAP  cases  compared  with  EO-VAP
ases (16.2%  vs.  4.8%,  p  =  0.02),  the  rates  of  A.
aumannii, K.  pneumonia  and  MRSA  were  similar
n these  groups.
atient outcomes
able  3 shows  the  outcomes  of  the  four  groups  of
atients  in  this  study.  The  ICU  mortality  (p  =  0.01),
ospital mortality  (p  = 0.002)  and  tracheostomy
p =  0.03)  rates  in  the  EO-VAP  group  were  signiﬁ-
antly lower  than  those  in  the  LO-VAP  group,  but
ere similar  to  those  of  the  EL-VAP  group  (12.7%  vs.
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Table  3  Outcome  of  ventilator  associated  pneumonia  (VAP).  Early  onset  VAP  occurred  within  4  days  of  intubation
and  hospital  admission.  Late  onset  VAP  occurred  after  4  days  of  hospital  admission.  EL-VAP  occurred  within  4  days
of  intubation  but  after  the  fourth  day  of  hospitalization.  LL-VAP  occurred  after  the  fourth  day  of  intubation  and
hospitalization.
Variable  Early  onset
VAP
N  =  63
Late  onset
VAP
N  =  331
P-Value
EO-VAP  vs.
LO-VAP
EL-VAP
n =  40
LL-VAP
n  =  291
P-Value
EL-VAP  vs.
LL-VAP
ICU  outcome,  N  (%) 8  (12.7) 93  (28.1) 0.01 10  (25.0) 83  (28.5) 0.64
Hospital  outcome,  N  (%)  15  (23.8)  159  (48)  0.0004  16  (40.0)  143  (49.1)  0.28
Tracheostomy,  N  (%)  28  (44.4)  194  (58.6)  0.04  20  (50.0)  174  (59.8)  0.24
ICU  LOS  (days),
mean  ±  SD
12.9  ±  7.4  23.3  ±  20.3  <0.0001  16.4  ±  12.0  24.2  ±  21.0  0.0009
Hospital  LOS  (days),
mean  ±  SD
47.1  ±  42.6  79.5  ±  109.4  <0.0001  89.0  ±  97.7  78.2  ±  111.0  0.56
MV  duration  (days),
mean  ±  SD
11.9  ±  7.0  21.5  ±  19.2  <0.0001  15.1  ±  11.8  22.4  ±  19.8  0.001
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5.0%,  p  =  0.11;  28.3%  vs.  40.0%,  p  =  0.08;  and  44.4%
s. 50.0%,  p  =  0.58,  respectively).  Likewise,  there
ere insigniﬁcant  differences  in  the  outcomes  of
atients  in  the  EL-VAP  and  LL-VAP  groups.
utcome predictors
n  the  adjusted  multivariate  logistic  regression
nalysis, LO-VAP  was  not  associated  with  increased
ospital  (OR,  0.87  95%  CI,  0.35—2.19,  p  =  0.77)
r ICU  (OR,  0.98;  95%  CI,  0.45—2.15,  p  =  0.97)
ortality compared  with  EO-VAP,  but  LO-VAP  was
ssociated  with  an  increased  risk  for  tracheostomy
OR, 2.26;  95%  CI,  1.27—4.04,  p  =  0.006).  Further,
either EL-VAP  nor  LL-VAP  was  associated  with
ncreased  ICU  (OR,  0.95;  95%  CI,  0.27—3.30,  and
R, 0.86;  95%CI,  0.34—2.19,  p  = 0.76,  respectively)
r hospital  mortality  (OR,  1.22;  95%  CI,  0.41—3.68,
nd OR,  0.95;  95%  CI,  0.43—2.10,  respectively)  com-
ared with  EO-VAP  (Table  4).  However,  LL-VAP  was
ssociated  with  an  increased  risk  of  tracheostomy
OR, 2.49;  95%  CI,  1.36—4.53,  p  =  0.003)  com-
ared with  EO-VAP.  The  predictors  of  ICU  mortality
ncluded age  (OR,  1.02;  95%  CI  1.0—1.03,  p  =  0.04),
hronic liver  disease  (OR,  5.63;  95%  CI  2.49—12.78,
 <  0.0001),  and  chronic  immunosuppression  (OR,
.80; 95%  CI,  1.22—6.42,  p  = 0.02).  The  predictors
f hospital  mortality  were  age  (OR,  1.03;  95%  CI
.02—1.05,  p  <  0.001),  APACHE  II  score  (OR,  1.08;
5% CI,  1.04—1.12,  p  < 0.001)  and  chronic  immuno-
uppression (OR,  2.96;  95%  CI,  0.98—8.93,  p  =  0.05).iscussion
ur  study  found  that  the  microorganisms  responsi-
le for  VAP  were  generally  comparable  regardless
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f  the  length  of  hospitalization  or  the  duration
f mechanical  ventilator  use  before  VAP  onset.
owever, Hemophilus  inﬂuenza  was  signiﬁcantly
ore common  and  P.  aeruginosa  was  less  frequent
n the  EO-VAP  group  compared  with  the  LO-VAP
roup. Additionally,  there  was  no  signiﬁcant  dif-
erence  in  the  presence  of  MRSA  and  potential
DROs (A.  baumannii,  K.  pneumoniae) between  the
roups. Further,  although  mortality  was  highest  in
he LL-VAP  group,  the  time  of  VAP  onset  was  not
ndependently  associated  with  mortality.
Prior  studies  have  shown  a higher  involvement  of
DROs in  LO-VAP  compared  with  EO-VAP  [30—33].
owever, globally,  recent  data  from  several  stud-
es have  revealed  that  the  causative  pathogens  in
O-VAP were  mostly  Gram-negative  organisms,  with
 high  prevalence  of  MDROs  [11,17,18,20,25,34].
n 2000,  Ibrahim  et  al.  reported  that  except  for
. aeruginosa, both  EO-  and  LO-VAP  were  caused
y similar  organisms  [18].  In  a recent  prospec-
ive multicenter  study  conducted  in  27  ICUs  from
ine European  countries,  Martin-Loeches  and  asso-
iates illustrated  that  50.7%  of  EO-VAP  episodes
ere associated  with  potentially  MDROs  [25].  An
nalysis of  496  patients  with  VAP  from  multiple  cen-
ers in  North  America,  South  America,  Europe  and
ustralia demonstrated  that  43.3%  of  the  organisms
solated  from  EO-VAP  were  MDROs  [17]. Addition-
lly, a  prospective  surveillance  study  conducted  in
3 hospitals  in  10  Asian  countries  on  997  patients
ith VAP  found  that  Acinetobacter  species,  P.
eruginosa, S.  aureus,  and  K.  pneumonia  were  the
ost common  causes  of  both  EO-  and  LO-VAP  [35].
imilarly, our  data  indicate  that  Gram-negative
icroorganisms  are  the  main  isolates  found  in  VAP
ases, regardless  of  the  diagnosis  timing  from  hospi-
al admission  and  invasive  mechanical  ventilation.
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Table  4  Multivariate  logistic  regression  analysis  for  outcomesa: ICU  mortality,  hospital  mortality,  need  for  tra-
cheostomy,  ICU  length  of  stay  and  hospital  length  of  stay:  early  onset  VAP  vs  late  onset  VAP,  early  onset  vs  EL-VAP
and  early  onset  vs  LL-VAP.
Predictors  Odds  ratio  (95%  CI)  P-Value
ICU  mortality
EO-VAP  vs.  LO-VAP 0.87  (0.35—2.19) 0.77
EO-VAP  vs.  EL-VAP 0.95  (0.27—3.30) 0.93
EO-VAP  vs.  LL-VAP  0.86  (0.34—2.19)  0.76
Age  1.02  (1.0—1.03)  0.04
Admission  category  —  trauma  0.25  (0.10—0.59)  0.002
PaO2/FiO2 0.99  (0.99—0.99)  0.01
Chronic  liver  disease  5.65  (2.49—12.78)  <0.001
Chronic  immunosuppression  2.80  (1.22—6.35)  0.02
Hospital  mortality
Early  onset  VAP  vs.  late  onset  VAP  0.98  (0.45—2.15)  0.97
Early  onset  VAP  vs.  EL-VAP  1.22  (0.41—3.68)  0.72
Early  onset  VAP  vs.  LL-VAP  0.95  (0.43—2.10)  0.90
Admission  category  —  trauma  0.20  (0.10—0.41)  <0.001
Age  1.03  (1.02—1.05)  <  0.001
APACHE  II  score 1.08  (1.04—1.12) <0.001
Chronic  immunosuppression 2.91  (0.97—8.75) 0.06
Tracheostomy
Early  onset  VAP  vs.  late  onset  VAP 2.26  (1.27—4.04) 0.006
Early  onset  VAP  vs.  EL-VAP 1.38  (0.60—3.17) 0.45
Early  onset  VAP  vs.  LL-VAP 2.49  (1.36—4.53) 0.003
Admission  category  —  trauma 2.41  (1.33—4.36) 0.004
Age  1.02  (1.01—1.03) 0.004
COPD  2.17  (0.89—5.24) 0.09
Chronic  liver  disease  0.32  (0.14—0.71)  0.005
Chronic  renal  disease  0.40  (0.19—0.81)  0.01
Predictors  Beta  coefﬁcient§ (95%  CI)  P-Value
ICU  length  of  stay,  days
EO-VAP  vs.  LO-VAP  6.12  (0.97  to  11.28)  0.02
EO-VAP  vs.  EL-VAP  0.25  (11.06  to  33.31)  0.94
EO-VAP  vs.  LL-VAP  7.42  (7.01  to  7.52)  0.01
Admission  category  —  trauma  −5.84  (−10.14  to  −1.53)  0.01
APACHE  II  score  −0.38  (−0.64  to  −0.13)  0.003
Chronic  liver  disease −8.35  (−14.76  to  −1.93)  0.01
Chronic  respiratory  disease  8.67  (3.39  to  13.95)  0.001
COMA  −3.31  (−7.01  to  0.38)  0.08
Hospital  length  of  stay,  days
EO-VAP  vs.  late  onset  VAP 44.32  (16.40  to  72.24)  0.002
EO-VAP  vs.  EL-VAP  49.68  (41.8  to  110.7)  0.02
EO-VAP  vs.  LL-VAP  43.43  (9.56  to  88.80)  0.003
APACHE  II  score  −1.49  (−2.69  to  −0.28)  0.02
Chronic  liver  disease  −40.14  (−75.39  to  −4.88)  0.03
ICU, intensive care unit; EO-VAP, early-onset VAP; EL-VAP, early-late VAP; LL-VAP, late-late VAP; PaO2/FiO2, partial pressure of
arterial oxygen to the fraction of inspired oxygen; APACHE II Score, acute physiology and chronic health evaluation; COPD, chronic
obstructive pulmonary disease; CI, conﬁdence interval.
a Note: In multivariate logistic regression analysis for outcomes we adjusted for: age, gender, APACHE II score, body mass
index, Glasgow Coma Scale, creatinine, INR, bilirubin, admission diagnosis, admission category, chronic co-morbidities (respiratory,
cardiovascular, renal, neurological), diabetes, hypertension, vasopressor use, location before referral to the ICU, acute respiratory
distress syndrome, failed extubation, accidental extubation, orogastric vs. nasogastric tube and prolonged antibiotics.
§ Beta coefﬁcient: if the regression beta coefﬁcient is positive, the interpretation is that for every 1-unit increase in the predictor
variable, the dependent variable will increase by the unstandardized beta coefﬁcient value. For example, the presence of late
onset VAP in our model increased ICU length of stay by 6.12 days compared with early onset VAP.
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ohe  impact  of  onset  time  on  the  isolated  pathogen
his  suggests  that  the  bacteriology  of  VAP  may
ot follow  an  ‘‘early  versus  late’’  pattern  and
hat there  may  be  a  microbiological  shift  in  the
athogens  responsible  for  ‘‘early  onset’’  VAP  favor-
ng MDROs.
Our  ﬁndings  are  of  paramount  importance  as  the
urrent  practice  guidelines  suggest  that  patients
ith EO-VAP  and  no  risk  factors  for  MDROs  should  be
reated with  narrow  spectrum  antibiotics  [8].  How-
ver, inadequate  antimicrobial  therapy,  whether
ith inappropriate  coverage  or  delayed  initiation,
as been  associated  with  higher  hospital  mortal-
ty in  patients  with  hospital-acquired  pneumonia  or
AP [36—38].  Kollef  and  colleagues  demonstrated
hat the  inappropriate  initial  antibiotic  therapy
f VAP  cases  attributed  to  potentially  antibiotic-
esistant Gram-negative  bacteria  was  associated
ith a  greater  30-day  mortality  [39]. Heyland  et  al.,
n a  multicenter,  randomized  trial  of  740  criti-
ally ill  patients  with  VAP  from  28  ICUs  in  Canada
nd the  United  States  showed  that  in  patients
ho had  an  infection  due  to  Pseudomonas  species,
cinetobacter  species,  and  MDR  Gram-negative
acilli, the  adequacy  of  initial  antibiotics  (84.2%  vs.
8.8%, p  < 0.001)  and  microbiological  eradication  of
nfecting organisms  (64.1%  vs.  29.4%,  p  <  0.05)  was
igher in  the  combination  group  compared  with  the
onotherapy  group  [40].  Thus,  it  may  be  reason-
ble to  use  broad  spectrum  combination  antibiotics
s an  empirical  therapy  for  all  VAP  cases  followed
y a  prompt  de-escalation  plan,  especially  in  insti-
utions  with  a  high  prevalence  of  MDROs.
Our  study  demonstrated  that  the  time  of  VAP
nset was  not  an  independent  predictor  of  either
CU or  hospital  mortality.  Other  investigators  have
ad similar  observations.  Mosconi  et  al.  compared
atients with  early  and  late-onset  pneumonia  and
iscovered  a  similar  rate  of  mortality  in  the  two
roups [41].  This  was  also  observed  by  Heyland
t al.  [42]  and  by  Ibrahim  et  al.  [18].  Giantsou
t al.  investigated  this  question,  focusing  on  diag-
osing pneumonia  by  bronchoalveolar  lavage,  and
ame to  the  same  conclusion  [11]. Hedrick  et  al.
ere unable  to detect  any  signiﬁcant  differences  in
ortality between  EO-  and  LO-pneumonia  [43].  In
he current  study,  multivariate  analysis  showed  that
igher APACHE  II  scores  and  the  presence  of  chronic
iver disease  were  associated  with  shorter  ICU  and
ospital  lengths  of  stay.  This  could  be  explained  by
he fact  that  patients  with  these  conditions  died
arlier  and  thus  had  a  shorter  length  of  stay.
The strengths  of  this  study  include  the  largeample size  and  prospective  data  collection.  Our
tudy has  several  limitations.  First,  this  was  a sin-
le center  study,  so  our  patient  population  may  not
e similar  to  those  at  other  institutions  and  our
m
a
c
t outcomes  169
esults  may  not  be  applicable  to  other  ICUs.  Sec-
nd, we  used  the  CDC  criteria  [23]  for  diagnosing
ealthcare-associated  pneumonia,  which  may  over-
stimate VAP  incidence  [18]. Third,  the  bacterial
solates from  the  VAP  cases  may  not  reﬂect  the  true
tiologic  pathogens  because  more  stringent  diag-
ostic procedures,  such  as  bronchoalveolar  lavage,
ere not  performed  in  most  cases.  However,  the
ptimal  diagnostic  approach  for  VAP  has  not  been
ell established  [44].
onclusions
his  study  demonstrated  that  in  most  VAP  cases,
he isolated  microorganisms  were  potential  MDROs,
egardless  of  the  duration  of  hospitalization  or
echanical  ventilation  use  before  VAP  onset.
urther, in  our  opinion,  the  old  concept  of  differen-
iating  pathogens  based  on  EO-  and  LO-VAP  may  no
onger be  helpful  in  choosing  the  correct  empirical
ntibiotic therapy.  Our  ﬁndings  also  emphasize  the
eed for  ICU-speciﬁc  information  on  VAP-causative
rganisms to  facilitate  appropriate  empiric  antimi-
robial therapy.  Finally,  out  data  support  what
eems  to  be  a global  shift  in  the  pathogens  causing
‘early  VAP’’.
ey message
 The  microorganisms  responsible  for  VAP  were
generally  similar  regardless  of  the  preceding
length of  hospitalization  or  time  on  mechanical
ventilator.
 There  were  no  signiﬁcant  differences  in  the  pres-
ence of  potentially  multidrug  resistant  organisms,
mainly A.  baumannii, K.  pneumonia  and  MRSA,
between early  and  late-onset  VAP  cases.
 The  time  of  onset  of  VAP  was  not  independently
associated  with  increased  mortality.
 There  appears  to  be  a  shift  in  the  pathogens  caus-
ing ‘‘early  onset  VAP’’.
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